SAN ANTONIO, Dec. 6 /PRNewswire/ -- More than 6,500 delegates from more than 80 countries are expected to attend the 27th Annual Charles A. Coltman, Jr., San Antonio Breast Cancer Symposium, December 8-11, 2004 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This symposium is internationally recognized as the leader focusing on breast cancer -- understanding its basic biology and clinical efforts toward prevention and treatment. Oral sessions and abstract posters will be presented throughout the Symposium. Some will reveal for the first time new and late breaking data, including promising information from clinical trials and studies, and recent diagnostic developments.
In addition to the more than 600 presentations, there will be four mini- symposia on special topics and five plenary speakers. The mini symposia will focus on:
-- Breast Cancer Risk Assessment
-- Epigenetics in Breast Cancer
-- Molecular Therapeutics - The Newest Agents and Targets
-- Breast Cancer in Younger Women
The plenary talks will be on:
-- The rise and current status of aromatase inhibitors in breast cancer
treatment
-- Stromal-epithelial interactions in normal human breast development
and cancer promotion
-- MRI screening for high risk patients
-- Interventions in telomerase action in human cancer cells
-- Meta-analysis on local therapy
The Annual William L. McGuire Memorial Lecture will be presented by Amy S. Langer, MBA, Former Executive Director, National Alliance of Breast Cancer Organizations, New York. The title of her presentation is "The fruits and frustrations of a decade of breast cancer advocacy."
A satellite symposium at the Marriott Rivercenter Hotel will follow the regular session on Saturday, December 11, covering the topic "Breaking the Five-Year SERM Barrier: Perspectives on Clinical Application of New Data & Strategies in the Adjuvant Setting." New data and strategies for aromatase inhibitors that are leading to shifts in treatment paradigms and changes in patient options for hormonal therapy in the adjuvant setting will be evaluated.
This meeting is sponsored by the San Antonio Cancer Institute, a research affiliation between the Cancer Therapy & Research Center and The University of Texas Health Science Center at San Antonio. The Symposium is supported by registration fees from the participants, corporate donations, and a conference grant from the American Cancer Society.
Contact: Jennifer Milikien, (210) 616-5550
jmilikien@ctrc.net
San Antonio Breast Cancer SymposiumCONTACT: Jennifer Milikien, +1-210-616-5550, or jmilikien@ctrc.net , forSan Antonio Breast Cancer Symposium
Web site: http://www.sabcs.org/
